NRIX Stock Price
$15.75 (+1.01%)
At 2024-05-30 20:00:00 ESTNurix Therapeutics, Inc
(NASDAQ:NRIX) 
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodul...
Website: http://www.nurixtx.com
Founded: 2009
Full Time Employees: 122
CEO: Arthur T. Sands
Sector: Healthcare
Industry: Biotechnology
Next Earnings Date: 2023-07-13
Share this website to your friends
NRIX - Daily
Date: 2024-05-31, O: 15.65, H: 16.13, L: 15.45, C: 15.75, Volume: 1,879,787
10EMA: 15.4320EMA: 15.0750EMA: 14.22100EMA: 12.84200EMA: 11.01
10EMA: 15.4320EMA: 15.0750EMA: 14.22100EMA: 12.84200EMA: 11.01
NASDAQ:NRIX Stock Key Statistics
| Basic Info: | |||
| Market Cap: | 846.10M | Exchange: | NASDAQ |
| Shares Outstanding: | 48,894,100 | Number of Employees: | 122 |
| Advanced Info: | |||
| Beta: | 2.038 | Return on Equity (ROE) ttm: | -66.00% |
| Return on Assets (ROA) ttm: | -45.00% | Earnings per Share (EPS) ttm: | -2.65 |
| Book value per Share: | 4.12 | Cash per Share: | 0.89 |
| Current ast per Share: | 4.51 | ||
| Key Ratios: | |||
| P/E ttm: | -5.95 | P/E forward: | |
| P/E ttm high: | -1.65 | P/E ttm low: | -7.1 |
| P/S ttm: | 10.46 | P/B ttm: | 5.48 |
| P/FCF ttm: | -10.08 | PEG ratio: | |
| Cash Ratios: | |||
| Cash Ratio ttm: | 0.57 | Quick Ratio ttm: | 2.79 |
| Current Ratio ttm: | 2.86 | ||
| Margins: | |||
| Gross Margin ttm: | 82.24% | EBITDA Margin ttm: | -184.12% |
| Operating Margin ttm: | -299.10% | Net Income Margin ttm: | -175.86% |
| Dividends: | |||
| Trailing Dividend yield: | Forward Dividend yield: | ||
| Payout Ratio ttm: | Ex-Dividend date: | None | |
| Target Prices: | |||
| Target Price High: | 53 USD | Target Price Low: | 11 USD |
| Target Price Mean: | 29.08 USD | Number of Analysts: | 12 |
| Debt: | |||
| Debt Ratio ttm: | 0.09 | Debt to Equity ttm: | 0.17 |
| Total Net Debt: | -20.66M | ||
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.